IDO1 and melanoma: However, despite the theoretical benefit of AhR modulation, phase III clinical trials to date have been ineffective—inhibition of IDO1 in combination with immune checkpoint inhibitors (ICI) showed no difference in survival compared to ICI alone in metastatic or unresectable melanoma [20].